First trimester biochemical screening for trisomy 21: the role of free p-hCG and pregnancy associated plasma protein
It is not clear how the data presented by Spencer et at.' support only their summary statement, that adding unconjugated oestriol (DE3) and pregnancy associated plasma protein A (PAPP-A) levels did not significantly improve the detection rate for Down's syndrome achieved with a combination of Cl/ fetoprotein (AFP) and free fJ-human chorionic gonadotrophin (fJ-hCG) levels. What their data shows in their Table 4 is that without free li-hCG any pair of AFP, UE3 and PAPP-A have a detection rate of 36-39%, and when free li-hCG is included this rises to 51-54070, that is by 15 percentage units. Moreover, the combinations of (free li-hCG + PAPP-A + UE3), (free li-hCG + AFP + PAPP-A + UE3) and, less relevant, (PAPP-A + UE3 + AFP) were excluded without comment from their table, so the readers cannot judge for themselves.
Although the authors state limitations to the use of PAPP-A by applying the Kolmogorov-Smimov test (their Table 3 -definition of the terms 'D' and 'P' would have helped), the message of their Table 2 is of a hierarchy of reduction in the median of PAPP-A>UE3>AFP (39%>33%>26%) from the unaffected to the affected pregnancies. Thus, as a corollary, relative changes should be simpler to detect in P APP-A than AFP. This impression is enhanced by presenting a Multiple of the Median (MoM) value of 0·62 for PAPP-A in their Figure 2 .
The apparent conflict in their Table 2 in PAPP-A between the log transformed means (unaffected 10glOX= -0,00159 corresponding to x=O·996; affected IOglOX=0'19958 corresponding to x= 1· 583) and the medians (unaffected 1'027; affected 0,624) are presumably due to proofreading errors.
When MoMs are compared (their Table 5 ), a subset of 12 pregnancies is used. The value of 0'795 for PAPP-A is not only worse than 0'62 but compares unfavourably with that of O'73 for AFP. Although crude MoMs for all 21 affected pregnancies can be extrapolated from their Table 2 -PAPP-A 0'61; AFP 0'74; UE3 0'67; and li-hCG I· 86-the true MoMs for AFP and UE3 for a1121 affected pregnancies should have been presented for direct comparison.
In a screening programme, the increase in marginal detection rate must justify the extra cost of additional analytes. It may well be that the Author's reply I thank Dr Breimer for giving me the opportunity to correct a remaining proof-reading error in our paper on first trimester Down's syndrome screening. The mean 10glO PAPP-A value quoted in Table 2 should have been -O' 19958 for the affected cases (corresponding to a mean of 0,63). The comment Breimer makes with regard to other combinations of analytes, other than those listed in Table 4 is well taken. We had not included all possible combinations in Table 4 in an attempt to make the table less complex. The combinations referred to by Breimer would have equally given detection rates of 53-54% and 43% for the combination without free fJ-hCG.
We did not include definitions of standard statistical terms. For those completely unfamiliar with Kolmogorov-Smirnov tests, D refers to the maximum absolute difference between the hypothetical cumulative distribution and the empirical cumulative distribution, whilst P is the probability.
Finally I do not understand Breimer's need to extrapolate 'crude MoM's' from Table 2 , the actual median values in the data set is quoted in Table 2 . To have tabulated all the data for each pregnancy is unnecessary, the point Table 5 attempts to show is how analyte values change from first to second trimester-a fact which has implications for the use of PAPP-A in a screening context.
